Literature DB >> 9456659

Inhibition of HIV infectivity by human saliva.

D Malamud1, T Nagashunmugam, C Davis, S Kennedy, W R Abrams, R Kream, H M Friedman.   

Abstract

OBJECTIVE: Human saliva is known to decrease HIV infectivity in vitro. The purpose of this study was to extend these findings and to focus on the mechanism of action of these salivary factor(s).
DESIGN: A number of viruses and several assay systems have been utilized to determine if the effect of submandibular saliva is directly on the virus, on the host cell, or on the virus-cell interaction.
MATERIALS AND METHODS: Submandibular saliva from seronegative donors was incubated with HIV-1, other retroviruses, or unrelated viruses. Viral infectivity was monitored either by determining p24 antigen levels in peripheral blood mononuclear cells or Sup T1 cells, or using HeLa cells expressing CD4 and an HIV derived long terminal repeat linked to the beta-galactosidase gene.
RESULTS: The inhibition of viral infectivity by submandibular saliva is specific for HIV-1. While inhibition increases with time of incubation of saliva with virus, pretreatment of cells with saliva does not inhibit HIV production, and saliva has only modest inhibitory effects when added to HIV-infected cells.
CONCLUSIONS: It appears that the effect of submandibular saliva on decreasing the infectivity of HIV-1 is directly on the virus, rather than on the host cell.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9456659     DOI: 10.1111/j.1601-0825.1997.tb00376.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  10 in total

Review 1.  Plausibility of HIV-1 Infection of Oral Mucosal Epithelial Cells.

Authors:  M C Herzberg; A Vacharaksa; K H Gebhard; R A Giacaman; K F Ross
Journal:  Adv Dent Res       Date:  2011-04

Review 2.  Antiviral activities in human saliva.

Authors:  D Malamud; W R Abrams; C A Barber; D Weissman; M Rehtanz; E Golub
Journal:  Adv Dent Res       Date:  2011-04

3.  Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.

Authors:  Shamim H Kazmi; Julian R Naglik; Simon P Sweet; Robert W Evans; Siobhan O'Shea; Jangu E Banatvala; Stephen J Challacombe
Journal:  Clin Vaccine Immunol       Date:  2006-08-23

Review 4.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

Review 5.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

6.  The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay.

Authors:  Habtom H Habte; Anwar S Mall; Corena de Beer; Zoë E Lotz; Delawir Kahn
Journal:  Virol J       Date:  2006-11-24       Impact factor: 4.099

7.  The inhibition of the Human Immunodeficiency Virus type 1 activity by crude and purified human pregnancy plug mucus and mucins in an inhibition assay.

Authors:  Habtom H Habte; Corena de Beer; Zoë E Lotz; Marilyn G Tyler; Leann Schoeman; Delawir Kahn; Anwar S Mall
Journal:  Virol J       Date:  2008-05-19       Impact factor: 4.099

8.  A comparative proteomic analysis of the soluble immune factor environment of rectal and oral mucosa.

Authors:  Laura M Romas; Klara Hasselrot; Lindsay G Aboud; Kenzie D Birse; T Blake Ball; Kristina Broliden; Adam D Burgener
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

9.  The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids.

Authors:  Robin G Mansour; Lisa Stamper; Frederick Jaeger; Erin McGuire; Genevieve Fouda; Joshua Amos; Kimberly Barbas; Tomoo Ohashi; S Munir Alam; Harold Erickson; Sallie R Permar
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

Review 10.  Mucus and Mucins: do they have a role in the inhibition of the human immunodeficiency virus?

Authors:  Anwar Suleman Mall; Habtom Habte; Yolanda Mthembu; Julia Peacocke; Corena de Beer
Journal:  Virol J       Date:  2017-10-06       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.